HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Wins Landmark Case Against German Government Over Desloratadine Switch

Executive Summary

Generics giant Novartis through its Hexal subsidiary has won an important case against the German Ministry of Health over a delayed prescription-to-OTC switch of desloratadine, which shows European Union Member States have got the authority to switch at a national level centrally authorized drugs. 

You may also be interested in...



German OTC Marketing Round-Up: Allergy Launches From Novartis, Hevert, Dermapharm And Bencard

OTC marketing news from Germany: A hard-won desloratadine launch from Novartis, two new products from Dermapharm, as well as homeopathic and probiotic alternatives from Hevert and Bencard. 

Novartis Wins Second Landmark German Case, This Time For Probiotics

Following a landmark win against the German government for the Rx-to-OTC switch of desloratadine last month, Novartis has again secured a victory in the German Higher Court system, this time to continue marketing its Biosan probiotics range in the country.

One In Two Germans Want More OTC Migraine Medicines, BAH Survey Finds

Just under 50% of Germans and 65% of German migraine sufferers would like to see more migraine medicines available OTC, according to a survey commissioned by the German Association of Pharmaceutical Manufacturers (BAH).

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel